THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Shannon Conley to Humans

This is a "connection" page, showing publications Shannon Conley has written about Humans.
Connection Strength

0.686
  1. Cell non-autonomous regulation of cerebrovascular aging processes by the somatotropic axis. Front Endocrinol (Lausanne). 2023; 14:1087053.
    View in: PubMed
    Score: 0.049
  2. Delineating the Clinical Phenotype of Patients With the c.629C>G, p.Pro210Arg Mutation in Peripherin-2. Invest Ophthalmol Vis Sci. 2022 07 08; 63(8):19.
    View in: PubMed
    Score: 0.047
  3. Microvascular contributions to age-related macular degeneration (AMD): from mechanisms of choriocapillaris aging to novel interventions. Geroscience. 2019 12; 41(6):813-845.
    View in: PubMed
    Score: 0.039
  4. The Role of the Prph2 C-Terminus in Outer Segment Morphogenesis. Adv Exp Med Biol. 2019; 1185:495-499.
    View in: PubMed
    Score: 0.037
  5. Rom1 converts Y141C-Prph2-associated pattern dystrophy to retinitis pigmentosa. Hum Mol Genet. 2017 02 01; 26(3):509-518.
    View in: PubMed
    Score: 0.032
  6. Characterization of Ribozymes Targeting a Congenital Night Blindness Mutation in Rhodopsin Mutation. Adv Exp Med Biol. 2016; 854:509-15.
    View in: PubMed
    Score: 0.030
  7. Gene therapy for PRPH2-associated ocular disease: challenges and prospects. Cold Spring Harb Perspect Med. 2014 Aug 28; 4(11):a017376.
    View in: PubMed
    Score: 0.027
  8. Rim formation is not a prerequisite for distribution of cone photoreceptor outer segment proteins. FASEB J. 2014 Aug; 28(8):3468-79.
    View in: PubMed
    Score: 0.026
  9. Insights into the mechanisms of macular degeneration associated with the R172W mutation in RDS. Hum Mol Genet. 2014 Jun 15; 23(12):3102-14.
    View in: PubMed
    Score: 0.026
  10. A perspective on the role of the extracellular matrix in progressive retinal degenerative disorders. Invest Ophthalmol Vis Sci. 2013 Dec 17; 54(13):8119-24.
    View in: PubMed
    Score: 0.026
  11. Increased cone sensitivity to ABCA4 deficiency provides insight into macular vision loss in Stargardt's dystrophy. Biochim Biophys Acta. 2012 Jul; 1822(7):1169-79.
    View in: PubMed
    Score: 0.022
  12. Structural and functional relationships between photoreceptor tetraspanins and other superfamily members. Cell Mol Life Sci. 2012 Apr; 69(7):1035-47.
    View in: PubMed
    Score: 0.022
  13. Nanoparticles for retinal gene therapy. Prog Retin Eye Res. 2010 Sep; 29(5):376-97.
    View in: PubMed
    Score: 0.020
  14. Focus on molecules: RDS. Exp Eye Res. 2009 Sep; 89(3):278-9.
    View in: PubMed
    Score: 0.019
  15. Nonviral ocular gene therapy: assessment and future directions. Curr Opin Mol Ther. 2008 Oct; 10(5):456-63.
    View in: PubMed
    Score: 0.018
  16. Alterations in human trabecular meshwork cell homeostasis by selenium. Exp Eye Res. 2006 Apr; 82(4):637-47.
    View in: PubMed
    Score: 0.015
  17. Selenium's effects on MMP-2 and TIMP-1 secretion by human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2004 Feb; 45(2):473-9.
    View in: PubMed
    Score: 0.013
  18. Comparative study of PRPH2 D2 loop mutants reveals divergent disease mechanism in rods and cones. Cell Mol Life Sci. 2023 Jul 19; 80(8):214.
    View in: PubMed
    Score: 0.013
  19. Prph2 disease mutations lead to structural and functional defects in the RPE. FASEB J. 2022 05; 36(5):e22284.
    View in: PubMed
    Score: 0.012
  20. Imaging retinal microvascular manifestations of carotid artery disease in older adults: from diagnosis of ocular complications to understanding microvascular contributions to cognitive impairment. Geroscience. 2021 08; 43(4):1703-1723.
    View in: PubMed
    Score: 0.011
  21. Retinal biomarkers for Alzheimer's disease and vascular cognitive impairment and dementia (VCID): implication for early diagnosis and prognosis. Geroscience. 2020 12; 42(6):1499-1525.
    View in: PubMed
    Score: 0.010
  22. ROM1 contributes to phenotypic heterogeneity in PRPH2-associated retinal disease. Hum Mol Genet. 2020 09 29; 29(16):2708-2722.
    View in: PubMed
    Score: 0.010
  23. Novel molecular mechanisms for Prph2-associated pattern dystrophy. FASEB J. 2020 01; 34(1):1211-1230.
    View in: PubMed
    Score: 0.010
  24. Age-related impairment of neurovascular coupling responses: a dynamic vessel analysis (DVA)-based approach to measure decreased flicker light stimulus-induced retinal arteriolar dilation in healthy older adults. Geroscience. 2019 06; 41(3):341-349.
    View in: PubMed
    Score: 0.009
  25. DNA nanoparticles are safe and nontoxic in non-human primate eyes. Int J Nanomedicine. 2018; 13:1361-1379.
    View in: PubMed
    Score: 0.009
  26. The K153Del PRPH2 mutation differentially impacts photoreceptor structure and function. Hum Mol Genet. 2016 08 15; 25(16):3500-3514.
    View in: PubMed
    Score: 0.008
  27. PRPH2/RDS and ROM-1: Historical context, current views and future considerations. Prog Retin Eye Res. 2016 05; 52:47-63.
    View in: PubMed
    Score: 0.007
  28. RDS Functional Domains and Dysfunction in Disease. Adv Exp Med Biol. 2016; 854:217-22.
    View in: PubMed
    Score: 0.007
  29. Therapeutic Approach of Nanotechnology for Oxidative Stress Induced Ocular Neurodegenerative Diseases. Adv Exp Med Biol. 2016; 854:463-9.
    View in: PubMed
    Score: 0.007
  30. Non-viral therapeutic approaches to ocular diseases: An overview and future directions. J Control Release. 2015 Dec 10; 219:471-487.
    View in: PubMed
    Score: 0.007
  31. Genomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype. FASEB J. 2015 Jun; 29(6):2535-44.
    View in: PubMed
    Score: 0.007
  32. Electrophysiological characterization of rod and cone responses in the baboon nonhuman primate model. Adv Exp Med Biol. 2014; 801:67-73.
    View in: PubMed
    Score: 0.006
  33. Gene therapy for Stargardt disease associated with ABCA4 gene. Adv Exp Med Biol. 2014; 801:719-24.
    View in: PubMed
    Score: 0.006
  34. Synthesis and characterization of glycol chitosan DNA nanoparticles for retinal gene delivery. ChemMedChem. 2014 Jan; 9(1):189-96.
    View in: PubMed
    Score: 0.006
  35. Persistence of non-viral vector mediated RPE65 expression: case for viability as a gene transfer therapy for RPE-based diseases. J Control Release. 2013 Dec 28; 172(3):745-52.
    View in: PubMed
    Score: 0.006
  36. A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium. Biomaterials. 2013 Sep; 34(29):7158-67.
    View in: PubMed
    Score: 0.006
  37. S/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA. Hum Mol Genet. 2013 Apr 15; 22(8):1632-42.
    View in: PubMed
    Score: 0.006
  38. Comparative analysis of DNA nanoparticles and AAVs for ocular gene delivery. PLoS One. 2012; 7(12):e52189.
    View in: PubMed
    Score: 0.006
  39. DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice. J Clin Invest. 2012 Sep; 122(9):3221-6.
    View in: PubMed
    Score: 0.006
  40. Expression and role of p53 in the retina. Invest Ophthalmol Vis Sci. 2012 Mar 15; 53(3):1362-71.
    View in: PubMed
    Score: 0.006
  41. AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. Invest Ophthalmol Vis Sci. 2011 May 10; 52(6):3051-9.
    View in: PubMed
    Score: 0.005
  42. Gene therapy in the Retinal Degeneration Slow model of retinitis pigmentosa. Adv Exp Med Biol. 2010; 664:611-9.
    View in: PubMed
    Score: 0.005
  43. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J. 2010 Apr; 24(4):1178-91.
    View in: PubMed
    Score: 0.005
  44. RPE65: role in the visual cycle, human retinal disease, and gene therapy. Ophthalmic Genet. 2009 Jun; 30(2):57-62.
    View in: PubMed
    Score: 0.005
  45. Aquaporin-1 expression and conventional aqueous outflow in human eyes. Exp Eye Res. 2008 Oct; 87(4):349-55.
    View in: PubMed
    Score: 0.004
  46. Nanoparticle applications in ocular gene therapy. Vision Res. 2008 Feb; 48(3):319-24.
    View in: PubMed
    Score: 0.004
  47. Barriers to productive transfection of trabecular meshwork cells. Mol Vis. 2005 Oct 26; 11:869-75.
    View in: PubMed
    Score: 0.004
  48. Longitudinal decline in lung function: evaluation of interleukin-10 genetic polymorphisms in firefighters. J Occup Environ Med. 2004 Oct; 46(10):1013-22.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES